Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

@article{ThussPatience2011PerioperativeCW,
  title={Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).},
  author={Peter C. Thuss-Patience and Ralf-Dieter Hofheinz and D. I. Arnold and Axel Florsch{\"u}tz and Severin Daum and Albrecht Kretzschmar and Luisa Mantovani-Loeffler and Dmitry Bichev and Benedikt Gahn and Guido Schumacher and Michael Kneba},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4053}
}
4053 Background: Perioperative chemotherapy with ECF or ECX is a standard approach in Europe for resectable gastro-esophageal cancer. Docetaxel significantly improves efficacy if added to cisplatin and 5-FU as palliative treatment. To translate this efficacy into the curative approach this phase II study investigates docetaxel (D), cisplatin (C) and capecitabine (X) in the perioperative setting. METHODS Pts with curatively resectable adenocarcinoma of the distal esophagus, gastroesophageal… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…